２００９

２０0９年
１．原著論文
1.     Hiroki Nishikawa, Shota Nakamura, Eiichi Kodama, Saori Ito, Keiko Kajiwara, Kazuki Izumi,Yasuko Sakagami, Shinya Oishi, Tadayasu Ohkubo, Yuji Kobayashi, Akira Otaka, Nobutaka Fujii,Masao Matsuoka  Electrostatically constrained ?-helical peptide inhibits replication of HIV-1resistant to enfuvirtide.  International Journal of Biochemistry and Cell Biology 41:891-899,2009


2.     Kazuki Izumi, Eiichi Kodama, Kazuya Shimura, Yasuko Sakagami, Kentaro Watanabe, SaoriIto, Tsuyoshi Watabe, Yukihiro Terakawa, Hiroki Nishikawa, Stefan G. Sarafianos, Kazuo Kitaura,Shinya Oishi, Nobutaka Fujii, Masao Matsuoka.  Design of peptide-based inhibitors for HIV-1 strainsresistant to T-20.  Journal of Biological Chemistry 284:4914-4920, 2009


3.     Takeshi Naito, Kazuki Izumi, Eiichi Kodama, Yasuko Sakagami, Keiko Kajiwara, HirokiNishikawa, Kentaro Watanabe, Stefan G. Sarafianos, Shinya Oishi, Nobutaka Fujii, MasaoMatsuoka.  SC29EK, a peptide fusion inhibitor with enhanced ?-helicity, inhibits replication ofhuman immunodeficiency virus type 1 mutants resistant to enfuvirtide.  Antimicrobal Agents andChemotherapy53:1013-1018, 2009


4.     Mariko Ueno, Eiichi N. Kodama, Kazuya Shimura, Yasuteru Sakurai, Keiko Kajiwara, YasukoSakagami, Shinya Oishi, Nobutaka Fujii, Masao Matsuoka. Synonymous mutations in stem-loop IIIof Rev responsive elements enhance HIV-1 replication impaired by primary mutations for resistanceto enfuvirtide.  Antiviral Research82:67-72, 2009


5.     Atsuko Hachiya, Kazuki Shimane, Stefan G.Sarafianos, Eiichi N. Kodama, Yasuko Sakagami,Fujie Negishi, Hirokazu Koizumi, Hiroyuki Gatanaga, Masao Matsuoka, Masafumi Takiguchi, ShinichiOka.  Clinical relevance of substitutions in the connection subdomain and RNase H domains of HIV-1 reverse transcriptase from a cohort of antiretroviral treatment-naive patients.AntiviralResearch82:115-121, 2009


6.     Shinya Oishi, Hirotaka Kamitani, Yasuyo Kodera, KentaroWatanabe, Kazuya Kobayashi,Tetsuo Narumi, Kenji Tomita, Hiroaki Ohno, Takeshi Naito, Eiichi Kodama, Masao Matsuoka andNobutaka Fujii. Peptide bond mimicry by (E)-alkene and (Z)-fluoroalkene peptide isosteres:synthesis and bioevaluation of alpha-helical anti-HIV peptide analogues.Organic & BiomolecularChemistry7:2872-2877, 2009


7.     Shinya Oishi, Yasuyo Kodera, Hiroki Nishikawa, Kamitani H, Tsuyoshi Watabe, Hiroaki Ohno,Tadafumi Tochikura, Kazuki Shimane, Eiichi Kodama, Masao Matsuoka, Fuminori Mizukoshi, HajimeTsujimoto H, Nobutaka Fujii. Design and synthesis of membrane fusion inhibitors against the felineimmunodeficiency virus.Bioorganic & Medicinal Chemistry17:4916-4920, 2009


8.     Tsuyoshi Watabe,Yukihiro Terakawa, Kentaro Watanabe, Hiroaki Ohno, Hiroaki Nakano, ToruNakatsu, Hiroaki Kato, Kazuki Izumi, Eiichi Kodama, Masao Matsuoka, Kazuo Kitaura, Shinya Oishi,Nobutaka Fujii. X-ray Crystallographic Study of an HIV-1 Fusion Inhibitor with the gp41 S138ASubstitution.Journal of Molecular Biology392:657-665, 2009


9.     Michinori Tanaka, Kazumi Kajiwara, Rei Tokiwa, Kentaro Watanabe, Hiroaki Ohno, HirokoTsutsumi, Yoji Hata, Kazuki Izumi, Eiichi Kodama, Masao Matsuoka, Shinya Oishi, Nobutaka Fujii.Bioorganic Synthesis of End-capped Anti-HIV Peptides by Simultaneous Cyanocysteine-mediatedCleavages of Recombinant Proteins.Bioorganic & Medicinal Chemistry17:7487-7492, 2009


10.     Kazumi Kajiwara, Kentaro Watanabe, Rei Tokiwa, Tomoko Kurose, Hiroaki Ohno, HirokoTsutsumi, Yoji Hata, Kazuki Izumi, Eiichi Kodama, Masao Matsuoka, Shinya Oishi, and NobutakaFujii. Bioorganic Synthesis of a Recombinant HIV-1 Fusion Inhibitor, SC35EK, with an N-TerminalPyroglutamate Capping Group.Bioorganic & Medicinal Chemistry17:7964?7970, 2009


11.     Eleftherios Michailidis, Bruno Marchand, Eiichi N. Kodama, Kamlendra Singh, MasaoMatsuoka, Karen A. Kirby, Emily M. Ryan, Ali M. Sawani, Eva Nagy, Noriyuki Ashida, HiroakiMitsuya, Michael A. Parniak, and Stefan G. Sarafianos. Mechanism of inhibition of HIV-1 reversetranscriptase by 4’-ethynyl-2-fluoro-2’-doxyadenosine triphosphate, a translocation defectivereverse transcriptase inhibitor.Journal of Biological Chemistry284:35681-35691, 2009



２．総説
1.     Shimura K, Kodama E. Pointer; Elvitegravir: a new HIV integrase inhibitor.AntiviralChemistry and Chemotherapy20:79-85, 2009

2.     児玉栄一、服部俊夫　HIV感染症と増殖のメカニズム-抗ウイルス剤の作用点を中心に-　特集　HIV感染症　流行の現状と最新の治療　日本内科学会雑誌 98:2754-2761, 2009


３．学会発表と招待講演
1.     Bruno Marchand, L Michailidis, E-I Kodama, E Ryan, M Matsuoka, N Ashida, H Mitsuya, ENagy, M Parniak, and S Sarafianos Mechanisms of Resistance and Hypersusceptibility toTranslocation-deficient Reverse Transcriptase Inhibitors. 16th conference on retroviruses andopportunistic infections Montreal, Canada Feb 8-11, 2009

2.     K.Shimura, E.Kodama, D.Nameki, Y.Sakagami, S.Oishi, N.Fujii, and M.Matsuoka ResistantProfile of the Electrostatically Constrained Next-generation HIV-1 Fusion Inhibitors. 16thconference on retroviruses and opportunistic infections Montreal, Canada Feb 8-11, 2009

3.     Kodama E. Drug design for resistant HIV. 10th Kumamoto AIDS seminar/AIDS GCOEInternational Symposium Satellite symposium, Kumamoto, Japan, Sep 30, 2009（招待講演）

4.     Hiroaki Mitsuya, Stefan G. Sarafianos, Eiichi Kodama, Hirotomo Nakata, Seiji Okada, andMichael A. Parniak 4′-Ethynyl-2-fluoro-2’-deoxyadenosine (EFDA), a translocation defective reversetranscriptase inhibitor with highly potent activity against diverse multi-drug-resistant HIV-1variants. 10th Annual Symposium on Antiviral Drug Resistance, Richmond, VA, Nov15-18, 2009.

5.     Matthew Schuckmann, Atsuko Hachiya, Ei-ichi N. Kodama, Bruno Marchand, EleftheriosMichailidis, Kamlendra Singh, Yasuko Sakagami, Shinichi Oka, and Stefan G. Sarafianos.Biochemical characterization of the HIV reverse transcriptase connection domain multi-class drugresistance mutation N348I. 10th Annual Symposium on Antiviral Drug Resistance, Richmond, VA,Nov15-18, 2009.

6.     Yee Tsuey Ong, Eleftherios Michailidis, Bruno Marchand, Matthew S. Schuckmann, KamlendraSingh, Ei-Ichi Kodama, Masao Matsuoka, Hiroaki Mitsuya, Eva Nagy, Michael A. Parniak, andStefan G. Sarafianos. The NNRTI-resistant Y181C HIV-1 reverse transcriptase is hyper-susceptibleto 4′-ethynyl-2-fluoro deoxyadenosine (EFDA). 10th Annual Symposium on Antiviral DrugResistance, Richmond, VA, Nov15-18, 2009.

7.     Atsuko Hachiya, Eiichi N. Kodama, Matthew M. Schuckmann, Karen A. Kirby, EleftheriosMichailidis, Yasuko Sakagami, Kamlendra Singh, Shinichi Oka, and Stefan G. Sarafianos. K70Qexpands multi-drug resistance (MDR) of HIV-1 containing “Q151M complex” reverse transcriptasemutations. 10th Annual Symposium on Antiviral Drug Resistance, Richmond, VA, Nov15-18, 2009.